Incyte reported third-quarter total revenue of $1.56 billion, a 14% increase year-over-year, driven by a 14% rise in total net sales to $1.32 billion. Jakafi net sales grew 4% to $827 million, while Opzelura and Hematology/Oncology portfolios surged 36% and 38%, respectively. The company raised its full-year 2026 net sales guidance to $5.21–$5.30 billion from the previous range of $5.13–$5.26 billion, citing strong commercial performance. Incyte operates in the biopharmaceutical industry, developing and commercializing medicines for hematology, oncology, and inflammation.
